| Product NDC: | 0024-5812 |
| Proprietary Name: | Aplenzin |
| Non Proprietary Name: | bupropion hydrobromide |
| Active Ingredient(s): | 522 mg/1 & nbsp; bupropion hydrobromide |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0024-5812 |
| Labeler Name: | sanofi-aventis U.S. LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022108 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20090330 |
| Package NDC: | 0024-5812-30 |
| Package Description: | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0024-5812-30) |
| NDC Code | 0024-5812-30 |
| Proprietary Name | Aplenzin |
| Package Description | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0024-5812-30) |
| Product NDC | 0024-5812 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | bupropion hydrobromide |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20090330 |
| Marketing Category Name | NDA |
| Labeler Name | sanofi-aventis U.S. LLC |
| Substance Name | BUPROPION HYDROBROMIDE |
| Strength Number | 522 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |